face to face
By chance, if the
products are still bit
expensive, there is a
precedent of having
a subsidy by the
government. If TB and
AIDS medicine are
offered free to patients,
on similar pattern it
can certainly happen
here too. Of course the
test has to be piloted
before it gets massively
distributed. It would
be an added advantage
46
BioVoiceNews | August 2017
for the team that has
also created a market
plan.
Are there any other
priorities apart
from AMR that
would be chosen for
the competition in
longer run?
We are trying to
make the surgeries
cost effective, which
as of now are highly
expensive. Infact,
there is a meeting
that being held at
Italy in December
this year where this
is one of the topics of
discussion. The basic
thought is to develop
affordable products for
masses in developing
nations. For example,
the biodegradable
screw for child related
torn ligaments in the
Europe is highly costly